SCHEMBL5519337

SCHEMBL5519337

CCOC(=O)C1CCCN(CCNC(=O)Nc2cc(C)nc3ccccc23)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 2/20 0.57
ADRA2A P08913 1/20 0.57
DRD2 P14416 1/20 0.57
SLC6A2 P23975 1/20 0.57
HTR2A P28223 1/20 0.57
HTR2C P28335 1/20 0.57
SLC6A4 P31645 1/20 0.57
TMEM97 Q5BJF2 1/20 0.57
SIGMAR1 Q99720 1/20 0.57
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 1/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
ATM Q13315 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5518936 0.90 UTS2R (0.61) UTS2RADRA2ADRD2SLC6A2HTR2A
Hydrochloric Acid SCHEMBL5532609 0.90 UTS2R (0.60) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL4862825 0.90 UTS2R (0.63) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5524873 0.86 UTS2R (0.61) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5519342 0.85 UTS2R (0.55) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5524917 0.85 UTS2R (0.55) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5530419 0.85 UTS2R (0.60) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5521736 0.84 UTS2R (0.58) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5527297 0.84 UTS2R (0.54) UTS2RADRA2ADRD2SLC6A2HTR2A
SCHEMBL5520770 0.83 UTS2R (0.57) UTS2RADRA2ADRD2SLC6A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010516-A1 Novel piperidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2007-01-11 US disclosed
US-20070010516-A1 Novel piperidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2007-01-11 US disclosed
US-20070010516-A1 Novel piperidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2007-01-11 US disclosed
EP-1641776-A1 NOVEL PIPERIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-04-05 EP disclosed
WO-2004099180-A1 NOVEL PIPERIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010516-A1 Novel piperidine derivatives UTS2R, VIPR2, NTSR2 UTS2R 1/4885ADRA2A 35/4885DRD2 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.